Angry wife gets Qatar Airways flight diverted to Chennai

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Bengaluru, July 2: Congress leader and seven-time MLA D K Shivakumar today took charge as the president of the Karnataka Pradesh Congress committee in the presence of senior leaders of the party.

The formal was held at the KPCC office in Bengaluru. The ceremony is said to be a first of its kind in the country as 10 lakh people from the remotest corners of the state — 462 blocks and 6,000 gram panchayats and municipalities across 7,800 locations —witnessed it online.

Dinesh Gundu Rao , MLA, and immediate past president, handed over the party flag to Mr. Shivakumar. Senior leaders Siddaramaiah, Mallikarjun Kharge, and other MLAs and MLCs attended the programme.

AICC general secretary in-charge of Karnataka K C Venugopal spoke on the occasion and lashed out at the Modi government for poor handling of economic and health issues in the country.

Mangaluru, Jan 8: A 23-year-old youth has been booked under the POCSO Act on charges of abduction and sexual abuse of a minor girl.

Police said on Wednesday day that the accused identified as Aneesh Dias, a resident of Chikkamadnur has reportedly gone absconding. The victim, who hails from Puttur, is a I PU college student.

The victim's parents had filed a missing complaint with Puttur Rural police as their daughter did not return home after leaving home for college. The police investigating the complaint traced the girl.